CLAIMS

~~1. An agent for the treatment or prophylaxis of a neurodegenerative disease, comprising an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.~~

~~2. The agent according to claim 1, wherein the nucleic acid encoding AIM or AIM fragment is incorporated in a viral vector.~~

~~3. The agent according to claim 2, wherein the viral vector is a viral vector selected from the group consisting of adeno-associated virus, adenovirus, lentivirus, and Sendai virus.~~

~~4. The agent according to claim 3, wherein the viral vector is an adeno-associated virus.~~

~~5. The agent according to claim 4, wherein the adeno-associated virus is AAV serotype 5 (AAV5) or AAV serotype 9 (AAV9).~~

~~6. The agent according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, multiple system atrophy, Pick disease, corticobasal degeneration, progressive supranuclear paralysis, amyotrophic lateral sclerosis, spinobulbar muscular atrophy, spinal progressive muscular atrophy, Huntington's disease, spinocerebella degeneration, hippocampus sclerosis, progressive myoclonus epilepsy, and dentatorubral-pallidoluysian atrophy.~~

~~7~~1. ~~A method for treating or preventing a neurodegenerative disease, comprising administering~~Use of AIM, an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment in the manufacture of a

medicament for treating or preventing a neurodegenerative disease ~~to a subject~~, wherein the medicament is to be delivered into the brain.

~~8~~2. The ~~method~~ use according to claim ~~7~~1, wherein the nucleic acid encoding AIM or AIM fragment is incorporated in a viral vector.

~~9~~3. The ~~method~~use according to claim ~~8~~2, wherein the viral vector is a viral vector selected from the group consisting of adeno-associated virus, adenovirus, lentivirus, and Sendai virus.

~~10~~4. The ~~method~~use according to claim ~~8~~2, wherein the viral vector is an adeno-associated virus.

~~11~~5. The ~~method~~use according to claim ~~10~~4, wherein the adeno-associated virus is AAV serotype 5 (AAV5) or AAV serotype 9 (AAV9).

~~12~~6. The ~~method~~use according to any one of claims ~~7~~ 1 to ~~11~~5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, multiple system atrophy, Pick disease, corticobasal degeneration, progressive supranuclear paralysis, amyotrophic lateral sclerosis, spinobulbar muscular atrophy, spinal progressive muscular atrophy, Huntington's disease, spinocerebella degeneration, hippocampus sclerosis, progressive myoclonus epilepsy, and dentatorubral-pallidoluysian atrophy.